Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/562,524		
INFORMATION DISCLOSURE			URE	Filing Date	September 13, 2006		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Wolfgang H. Dillmann		
				Art Unit	1633		
				Examiner Name	James Schultz		
Sheet	1	of	1	Attorney Docket Number	UCSD1620-1		

NON PATENT LITERATURE DOCUMENTS								
AA	Fisher et al., "Overexpression of Sorcin in the Murine Heart Modulates Cardiac Performance, Circulation", October 2000, Vol. 102, No. 18, page 296, 1448.							
AB	Suarez et al., "In vivo Adenoviral Gene Transfer of Sorcin Increases Cardiac Contractility Circulation", November 2002, Vol. 106, No. 19, Supp. Page. 29, 144.							
AC	Suarez et al., "In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy", Am. J. Physiol. Heart Circ. Physiol., 2004 Jan; 286(1):H68-75, Epub. 2003 Sep 4.							
 		-						
	AA AB	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Fisher et al., "Overexpression of Sorcin in the Murine Heart Modulates Cardiac Performance, Circulation", October 2000, Vol. 102, No. 18, page 296, 1448. Suarez et al., "In vivo Adenoviral Gene Transfer of Sorcin Increases Cardiac Contractility Circulation", November 2002, Vol. 106, No. 19, Supp. Page. 29, 144. Suarez et al., "In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy", Am. J. Physiol. Heart Circ. Physiol., 2004 Jan;						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.